The Australian Cancer Research Foundation is dedicated to ending cancer. We fund cutting-edge and collaborative research projects with a focus on speeding up discoveries in cancer prevention, diagnosis and cure.
From studies that will give new hope to children who have relapsed, to revolutionising radiotherapy treatment by minimising the side-effects and the cost of the technology – we are very excited by the impact that your donations to the ACRF will have.
If you would like to give a Christmas Gift to cancer research this December, please donate here. If you’re interested in allocating your donation to a specific research project, please see your options below.
The ACRF Precision Medicine Centre for Childhood Cancer, Children’s Cancer Institute, Sydney
A new specialised medicine centre for children at high risk of treatment failure.
ACRF Facility for Molecular Imaging Agents in Cancer, UQ Centre for Advanced Imaging, Brisbane
Technologies for cancer imaging & treatment for humans & companion animals with cancer.
We would love for you to help give these projects a kick-start this December; either with a donation in lieu of traditional Christmas gifts or simply because, at this special time of year, we go that extra step for the people and causes we’re passionate about.
However, if you would prefer your Christmas donation to go to all types of cancer, where ever it is needed most, then please click the link below:
The ACRF Precision Medicine Centre for Childhood Cancer
Children’s Cancer Institute, Sydney
This Australian Cancer Research Foundation (ACRF) funding will enable the establishment of a unique Precision Medicine Centre which heralds a new era in childhood cancer research and treatment. We believe this new approach has the very real potential to substantially improve patient outcomes and survival rates.
From the Children’s Cancer Institute’s many years of research, it’s become clear that a ‘one size fits all’ approach to treating children with cancer does not work, since one in five children still die from their disease. The ACRF funding will help Children’s Cancer Institute, together with our partners at Sydney Children’s Hospital, Randwick, to develop a precision medicine platform which will give Australian children diagnosed with the most aggressive cancers the best chance of survival.
The ACRF Precision Medicine Centre for Childhood Cancer will provide the capability for every newly-diagnosed Australian high risk childhood cancer patient, and every child who relapses following treatment, to have their therapy individually and uniquely personalised, based on a combination of genomic and molecular data relating to their own particular cancer, followed by monitoring of the response of their own tumour cells, growing in the laboratory, to specifically selected anti-cancer drugs.
The genomic revolution has given us unprecedented opportunities to study the underlying causes and characteristics of individual patients’ cancers and, with the establishment of the ACRF Precision Medicine Centre, we will now be able to more accurately diagnose and predict disease outcome; provide earlier intervention; identify new treatment regimens; reduce toxic side effects of treatment; and, ultimately, realise our vision of saving the lives of all children with cancer.
The ACRF Image-X Institute
The Sydney University Central Clinical School, Sydney
The ACRF will support the creation of a new cancer research institute, The ACRF Image-X Institute: Eradicating Cancer through Innovation in Imaging and Targeted X-ray Therapy.
The institute will link technological innovation with cancer research and treatment, providing a site and forum where academia, medicine, industry and government can advance the science and clinical practice of cancer treatment. The institute will bring tangible real-world benefit to cancer patients undergoing cancer imaging and treatment procedures, with three interconnected themes.
This new institute will revolutionise cancer imaging, creating new and better cancer imaging methods that will allow more precise delineation of where to target the radiation treatment beams. More advanced cancer imaging will increase cure rates and reduce the human and economic costs of treatment-related side effects.
It will pioneer targeted radiotherapy where the x-ray beams are focused on the most aggressive and resistant cancers, increasing survival and reducing the chance of metastases.
They will enable global access to cancer radiotherapy by developing targeted X-ray radiotherapy systems that address both the high cost and limited availability of this important treatment technology: 135 countries around the world currently don’t have access to appropriate radiotherapy treatment.veterinary oncologists from UQ’s School of Veterinary Science and from the Brisbane Veterinary Specialist Centre.
ACRF Breakthrough Technologies Laboratory
Walter & Eliza Hall Institute, Melbourne
This year, more than 100,000 Australians will be diagnosed with cancer. Despite recent improvements in treatments for some types of cancer, more than 43,000 Australians still die from cancer each year. New treatments for cancer are urgently needed.
With support from the Australian Cancer Research Foundation, the Walter and Eliza Hall Institute is establishing the ACRF Breakthrough Technologies Laboratory to advance new treatments for many of Australia’s most common, and most deadly cancers, including cancers of the blood (leukaemia, lymphoma), breast, ovary, lung and bowel.
The laboratory will enhance and accelerate the research of more than 1000 cancer researchers through the Victorian Comprehensive Cancer Centre, a collaborative network of Victorian hospitals and research centres improving the prevention, diagnosis and treatment of cancer.
The ACRF Breakthrough Technologies Laboratory will provide cancer researchers with access to first-in-Australia technology providing new insights into how cancer develops, and how it can be more effectively treated.
Defining the molecular causes of cancer
Molecular technologies that modify specific genes within cancer cells have provided immense insights into how cancers develop, progress and respond to treatments.
The ACRF Breakthrough Technologies Laboratory will be the first facility in Australia to offer new state-of-the-art technology to target specific genes in cancer. This will provide researchers with the opportunity to make important new insights into how cancer develops, and how cancer cells respond to treatment.
Developing new treatments for cancer
Recently, ‘targeted therapies’ have shown considerable promise for treating certain cancers. These medicines interfere with specific proteins crucial for the function of cancer cells.
The ACRF Breakthrough Technologies Laboratory will give Australia’s cancer researchers unprecedented capabilities to discover and develop new targeted therapies for cancer.
ACRF Facility for Molecular Imaging Agents in Cancer
University of Queensland Centre for Advanced Imaging, Brisbane
ACRF funding will allow the establishment of the “ACRF Facility for Molecular Imaging Agents in Cancer (AFMIAC)” at the Centre for Advanced Imaging at The University of Queensland, a world class facility for the development and validation of novel molecular imaging agents for cancer. AFMIAC brings together cutting-edge capabilities for the synthesis of novel cancer diagnostic agents and for preclinical and human imaging.
Funding will allow the purchase of a scanner for large animal and human research, helping to unlock the potential of molecular imaging by enabling a comprehensive, multidisciplinary research program in developing, validating and utilizing agents to detect, characterise and monitor cancer at high resolution.
The research platform in AFMIAC will enable a new paradigm for cancer drug development, helping to improve the success rate of new cancer drugs by harnessing the power of PET microdosing in humans and Comparative Oncology, the study of spontaneous cancer in companion animals.
The first Comparative Oncology program in Australia will be established, bringing together cancer researchers and veterinary oncologists from UQ’s School of Veterinary Science and from the Brisbane Veterinary Specialist Centre.